DXR News & Events

Daxor Corporation continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. "This milestone marks another significant step in our regional expansion and underscores the critical role of precise volume assessment in patient care," said Michael Feldschuh, Daxor CEO and President. "With 98% accuracy, our technology empowers clinicians to move beyond 'best guesses' to data-driven fluid management. By utilizing our ezBVA Lab service, clinicians can implement our gold-standard diagnostic into the outpatient setting, which has reimbursement codes with no capital investment. This can meaningfully contribute significantly to improving patient outcomes and reducing healthcare costs."

Daxor Corporation announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, subject to its completion of required regulatory filings and approvals. This transition reflects the sustained rapid scaling and strategic maturation of the Company's core diagnostic technology operating business. The Company's principal focus remains the development and commercialization of its market-leading Blood Volume Analysis technology. This is the only FDA-cleared diagnostic blood test providing objective, patient-specific quantification of a patient's total blood volume status and composition. Key Highlights of the Transition: Reaffirmed Focus on Operations: This transition validates the success of management's strategy to prioritize and rapidly grow the core BVA technology division. This growth has been marked by significant developmental milestones, including revenue increases, new hospital system and medical practice customer acquisitions, and recent FDA-clearance of its next generation blood volume analyzer; Alignment of Financial Profile: Operational growth has evolved to a point where the Company's financial profile is now more accurately and appropriately represented under the Exchange Act framework, aligning regulatory status with the Company's primary identity as an innovative medical device and diagnostic technology firm; Enhanced Investor Clarity: Reporting under the Exchange Act will simplify financial disclosures and provide investors with standardized GAAP metrics and benchmarks in line with, and directly comparable to other publicly traded medical diagnostic companies. This alignment is expected to improve transparency and garner deeper institutional interest while expanding analyst coverage. The Company anticipates completing the necessary regulatory steps to fully effectuate the change in reporting status by the end of the second quarter, subject to completion of required regulatory filings and approvals.

Daxor Corporation entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Company are expected to be approximately $9M, before deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital. Lake Street Capital Markets is acting as the exclusive placement agent for the offering.